Boston Scientific Corporation acquired the remaining 65% of Cryterion Medical Inc, a privately held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation (AF), that it did not previously own for $202 million. Our firm represented Boston Scientific in both its initial Series A investment in Cryterion Medical and the ultimate acquisition.
Read Boston Scientific’s press release for more information.
